Trial · NCT05788289
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
NCT05788289, Phase 2, Terminated, Memorial Sloan Kettering Cancer Center; results first posted 2025-04-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma. Trials, record NCT05788289. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05788289
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
- NCT number
- NCT05788289
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Mantle Cell Lymphoma, MCL
- Interventions
- Tafasitamab, Lenalidomide
- First posted
- 2023-03-28
- Last updated
- 2025-05-25
- Results first posted
- 2025-04-20
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate/ORR | completion of 12 cycles of treatment (each cycle is 28 days) or at treatment discontinuation, whichever comes first | Overall Response Rate/ORR is defined as the percent of participants who achieve Complete Response/CR or Primary Response/PR |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Response Rate/ORR | completion of 12 cycles of treatment (each cycle is 28 days) or at treatment discontinuation, whichever comes first | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate/ORR | Participants With Mantle Cell Lymphoma | Participants with response | 1 | Participants | |
| Overall Response Rate/ORR | Participants With Mantle Cell Lymphoma | Participants without response | 3 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Participants With Mantle Cell Lymphoma | 4 | |
| Overall Study | COMPLETED | Participants With Mantle Cell Lymphoma | 1 | |
| Overall Study | NOT COMPLETED | Participants With Mantle Cell Lymphoma | 3 |
Source ClinicalTrials.gov
Adverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Participants With Mantle Cell Lymphoma | 1 | 4 | |
| other | Fatigue | General disorders | Participants With Mantle Cell Lymphoma | 1 | 4 | |
| other | Infusion related reaction | Injury, poisoning and procedural complications | Participants With Mantle Cell Lymphoma | 1 | 4 | |
| other | Nausea | Gastrointestinal disorders | Participants With Mantle Cell Lymphoma | 1 | 4 | |
| other | Creatinine increased | Investigations | Participants With Mantle Cell Lymphoma | 1 | 4 | |
| other | Platelet count decreased | Investigations | Participants With Mantle Cell Lymphoma | 1 | 4 | |
| other | Dysphagia | Gastrointestinal disorders | Participants With Mantle Cell Lymphoma | 1 | 4 | |
| other | Edema face | General disorders | Participants With Mantle Cell Lymphoma | 1 | 4 | |
| other | Generalized muscle weakness | Musculoskeletal and connective tissue disorders | Participants With Mantle Cell Lymphoma | 1 | 4 | |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Participants With Mantle Cell Lymphoma | 1 | 4 |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Participants With Mantle Cell Lymphoma | 4 | 4 |
| Total, other adverse events | Participants With Mantle Cell Lymphoma | 4 | 4 |
| Total, serious adverse events | Participants With Mantle Cell Lymphoma | 4 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05788289
GET https://conductscience.org/api/trials/v1/NCT05788289/registered